Voting responses from the attendees. The figures denote the percentage of positive (“yes”) responses to each question.
| Does this measure fulfill the following requirements of the OMERACT filter? | ||||
|---|---|---|---|---|
| Measure | Truth | Discrimination | Feasibility | Should this measure be considered for further study? |
| PsA Index | 47 | 64 | 86 | 73 |
| AM_DF1 | 67 | 40 | 71 | 25 |
| AM_DF2 | 74 | 82 | 62 | 70 |
| CPDAI | 94 | 88 | 69 | 88 |
| CPDAI new | 89 | 78 | 65 | 53 |
| DAPSA | 41 | 36 | 66 | 19 |
| DAS28 | 37 | 27 | 73 | 28 |
AM1_DF: composite score based on desirability functions; AM2_DF: AM1_DF with addition of PASI (Psoriasis Area and Severity Index); CPDAI: Composite Psoriatic Disease Activity Index; CPDAI new: CPDAI with new cutoffs (see text); DAPSA: Disease Activity for Psoriatic Arthritis; DAS28: Disease Activity Score for 28 joints; OMERACT: Outcome Measures in Rheumatology; PsA Index; putative new composite score for PsA.